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fworden@med.umich.eduAbstractEffective adverse event (AE) management is critical to maintaining patients on
anticancer therapies. The DECISION trial was a multicenter, randomized, double-blind,
placebo-controlled, Phase 3 trial which investigated sorafenib for treatment of
progressive, advanced, or metastatic radioactive iodine-refractory, differentiated thyroid
carcinoma. Four hundred and seventeen adult patients were randomized (1:1) to
receive oral sorafenib (400 mg, twice daily) or placebo, until progression, unacceptable
toxicity, noncompliance, or withdrawal. Progression-free survival, the primary endpoint
of DECISION, was reported previously. To elucidate the patterns and management of
AEs in sorafenib-treated patients in the DECISION trial, this report describes detailed,
by-treatment-cycle analyses of the incidence, prevalence, and severity of hand–foot skin
reaction (HFSR), rash/desquamation, hypertension, diarrhea, fatigue, weight loss,
increased serum thyroid stimulating hormone, and hypocalcemia, as well as the
interventions used to manage these AEs. By-cycle incidence of the above-selected AEs
with sorafenib was generally highest in cycle 1 or 2 then decreased. AE prevalenceKey Words
" differentiated thyroid cancer
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" targeted therapy
" tyrosine kinase inhibitor
" adverse eventsicensed under a Creative Commons
.0 Unported License.
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22 :6 878generally increased over cycles 2–6 then stabilized or declined. Among these AEs, only
weight loss tended to increase in severity (from grade 1 to 2) over time; severity
of HFSR and rash/desquamation declined over time. AEs were mostly grade 1 or 2,
and were generally managed with dose interruptions/reductions, and concomitant
medications (e.g. antidiarrheals, antihypertensives, dermatologic preparations). Most
dose interruptions/reductions occurred in early cycles. In conclusion, AEs with sorafenib
in DECISION were typically grade 1 or 2, occurred early during the treatment course,
and were manageable over time.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0252
q 2015 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.Endocrine-Related Cancer
(2015) 22, 877–887IntroductionThe early identification and proactive management of
adverse events (AEs) are fundamental to oncology practice
and particularly to the optimal use of newer, targeted
anticancer therapies such as sorafenib – an oral multi-
kinase inhibitor of vascular endothelial growth factor
receptor (VEGFR)-1, VEGFR-2 and VEGFR-3, RET
(including RET/PTC), RAF (including BRAFV600E), and
platelet-derived growth factor receptor b (Wilhelm et al.
2004, Carlomagno et al. 2006). Sorafenib has demon-
strated a consistent safety profile across tumor types. AEs
associated with sorafenib are predominantly grade 1/2,
non-life threatening, and manageable. The most com-
monly reported AEs include hand–foot skin reaction
(HFSR), rash/desquamation, hypertension, diarrhea, fati-
gue, and weight loss (Escudier et al. 2007, Llovet et al.
2008, Cheng et al. 2009, Brose et al. 2014a).
DECISION was a large Phase 3 randomized, placebo-
controlled trial in patients with locally advanced or
metastatic radioactive iodine (RAI)-refractory differentiated
thyroid cancer (DTC); sorafenib significantly improved
progression-free survival (PFS) vs placebo (hazard ratio
0.59; 95% CI 0.45–0.76; P!0.0001; median PFS 10.8 vs 5.8
months respectively) (Brose et al. 2014a). Given the long
duration of sorafenib therapy that was observed in this trial
(median 10.6 months; interquartile range 5.3–15.7), it is
particularly important to understand its safety profile in this
setting. DECISION, as the first large-scale trial in patients
with RAI-refractory DTC, may provide insight into the
management of patients receiving sorafenib in this setting.
Here we report a detailed, by-cycle analysis of the
incidence, prevalence, and severity of the most commonly
reported and clinically relevant treatment-emergent AEs,
as well as the associated dose modifications in patients
treated with sorafenib in the DECISION trial. We also
consider the interventions used to manage these AEs.Materials and methods
Study design
DECISION was a multicenter, randomized, double-blind,
placebo-controlled, Phase 3 trial that was conducted in
18 countries in Europe, Asia, and North America. Study
details have been previously reported (Brose et al. 2011,
2014a). Briefly, patients with locally advanced or meta-
static RAI-refractory DTC (papillary, follicular (including
Hu¨rthle cell), or poorly differentiated) could be enrolled
if their disease had progressed within the past 14 months
and they had at least one measurable lesion by
computed tomography or magnetic resonance imaging.
Disease progression and measurable tumors were
defined according to Response Evaluation Criteria in
Solid Tumors (RECIST v1.0) (Therasse et al. 2000). Patients
were required to be aged R18 years; have an Eastern
Cooperative Oncology Group (ECOG) performance status
of 0–2; adequate bone marrow, liver, and renal function;
and serum thyroid stimulating hormone (TSH)
!0.5 mIU/l.
Patients were randomized (1:1) to receive either
sorafenib 400 mg (2!200 mg tablets) twice daily or
matching placebo. Treatment was continued until disease
progression, unacceptable toxicity, noncompliance, or
withdrawal of consent. Treatment cycle length was
28 days. Patients all gave written informed consent. Trial
conduct and patient safety were monitored by an
independent data monitoring committee (Brose et al.
2014a). The conduct of this clinical study met all local
legal and regulatory requirements. The study was
conducted in accordance with the ethical principles
originating in the Declaration of Helsinki and the
International Conference on Harmonization (ICH) guide-
line E6: Good Clinical Practice.
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research F Worden et al. Sorafenib safety in
RAI-refractory DTC
22 :6 879Analysis of dose modifications by treatment cycle
Study drug interruption (and reintroduction), dose
reduction (and re-escalation), and permanent discontinu-
ation were employed based on protocol-defined criteria,
which differed for hematologic AEs, skin toxicities,
hypertension, and any other AEs (Supplementary Tables 1,
2, 3 and 4, see section on supplementary data given at the
end of this article) (Brose et al. 2014a). Dose levels were
800 mg (starting dose), 600 mg (divided doses: 400 and
200 mg), 400 mg (divided: 2!200 mg), and 200 mg
per day. After dose reductions, the protocol allowed
re-escalation upon resolution of the AE.
Dose modifications and treatment discontinuations
due to AEs were recorded by treatment cycle. Dose
reduction during a treatment cycle was defined as
patients receiving at least one daily dose of !800 mg
during that cycle.Analysis of common AEs by treatment cycle
Patients were assessed for safety every 28 days (i.e. once
every cycle) for the first nine treatment cycles, and then
every 56 days thereafter for the duration of treatment and
30 days after the last dose. The detailed analyses per cycle
reported here are limited to treatment cycles 1–9.
The overall incidence of AEs was reported previously
(Brose et al. 2014a). The by-cycle incidence, prevalence,
and severity of the following AEs were assessed in detail:
HFSR, rash/desquamation, hypertension, diarrhea, fatigue,
weight loss, increased serum TSH, and hypocalcemia. With
the exception of HFSR and elevated TSH, all other AEs were
reported and graded using the National Cancer Institute
Common Terminology Criteria for AEs (CTCAE) v3.0 and
Medical Dictionary for Regulatory Activities (MedDRA)
v15.1 terminology (National Cancer Institute 2006,
International Conference on Harmonisation 2006). The
severity of HFSR was assessed using study-specific grading
definitions (Supplementary Table 5, see section on supple-
mentary data given at the end of this article); example
photographs illustrating the appearance of different HFSR
grades in sorafenib-treated patients are shown in
Supplementary Figure 1 (see section on supplementary
data given at the end of this article) (Chu et al. 2008).
Elevated TSH (O0.5 mIU/l requiring an increase in the dose
of thyroxine replacement) was a study-specific AE, with a
maximum severity of grade 1.
The by-cycle incidence of an AE was defined as the
number of patients with that AE starting or worsening
in a particular cycle. The prevalence of an AE duringhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0252
q 2015 The authors
Printed in Great Britaina treatment cycle was defined as the number of patients
with an AE occurring (new or continuing) during that
treatment cycle. Both incidence and prevalence are
expressed as a percentage of patients at risk in that cycle.Results
Patients
The intention-to-treat population consisted of 417
patients of whom 207 were randomized to sorafenib and
210 to placebo. Patient demographics and baseline clinical
characteristics were generally well balanced between the
treatment groups (Brose et al. 2014a). Median age was 63
years and performance status was principally ECOG 0
(62%) or 1 (34%).Safety findings for the entire treatment period
Overall AE incidence and dose modifications
Safety outcomes across the entire DECISION study treat-
ment period have been reported previously; an overview of
these data is shown in Tables 1 and 2 (Brose et al. 2014a).
Overall, the most common AEs in the sorafenib arm were
HFSR, diarrhea, alopecia, rash/desquamation, fatigue,
weight loss, and hypertension (Table 2). The most common
serious AEs (i.e. those reported by R2% of patients
receiving sorafenib) were dyspnea, pleural effusion, and
secondary malignancy (principally squamous cell carci-
noma of the skin; nZ7) (Table 1). Of the specific AEs
analyzed in detail in this report, those in the sorafenib
group considered to be serious events were fatigue (three
patients), weight loss and rash/desquamation (two patients
each), as well as HFSR, diarrhea, and hypocalcemia (one
patient each). The single patient who experienced serious
grade 4 hypocalcemia was hospitalized but recovered with
calcium substitution. No case of serious hypertension was
reported in this study. There were 12 deaths in the sorafenib
group (median time on study 130.5 days) and six in the
placebo arm (median time on study 73 days), most of which
were attributed to disease progression (seven in the
sorafenib group, four in the placebo group; Table 1).
One death in each group was attributed to the study drug.
One patient receiving sorafenib died of a myocardial
infarction 427 days (14.0 months) after starting treatment
and one patient receiving placebo died of a subdural
hematoma 289 days (9.5 months) after starting treatment
(Brose et al. 2014a).
Study drug interruptions, dose reductions, and
permanent discontinuations due to the specific AEsPublished by Bioscientifica Ltd.
Table 1 Safety overview (safety population)
Sorafenib (nZ207) Placebo (nZ209)
Median duration of treatment, months (IQR) 10.6 (5.3–15.7) 6.5 (3.3–12.9)
Mean daily dose, mg (SD) 651 (159) 793 (26)
Dose interruptions, n (%) 137 (66.2) 54 (25.8)
Dose reductions, n (%) 133 (64.3) 19 (9.1)
Any treatment-emergent AE, n (%) 204 (98.6) 183 (87.6)
Grade 3/4 treatment-emergent AEs, n (%) 133 (64.3) 63 (30.1)
AEs leading to withdrawals, n (%) 39 (18.8) 8 (3.8)
Treatment-emergent deaths, n (%) 12 (5.8)a 6 (2.9)b
Deaths attributed to study drug, n (%) 1 (0.5) 1 (0.5)
Serious AEs, n (%) 77 (37.2) 55 (26.3)
Serious AEs reported by R2% of patients receiving sorafenib, n (%)
Secondary malignancy 9 (4.3) 4 (1.9)
Dyspnea 7 (3.4) 6 (2.9)
Pleural effusion 6 (2.9) 4 (1.9)
AEs, adverse events; IQR, interquartile range.
aProgressive disease, 7; unknown, 2; lung infection, 1; chronic obstructive lung disease, 1; myocardial infarction, 1.
bProgressive disease, 4; pulmonary embolism, 1; subdural hematoma, 1.
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course of treatment, are shown in Table 3. In the sorafenib
group, HFSR was the most common reason for treatment
interruption (in 26.6% of patients) and dose reduction
(33.8%). Diarrhea was the next most common reason for
dose reduction (13.5%). Overall, permanent discontinu-
ation of the study drug due to AEs occurred in 18.8% of
patients in the sorafenib group and 3.8% in the placebo
group (Table 1); 11 patients (5.3%) discontinued sorafenib
treatment due to HFSR, whereas discontinuations due to
other AEs were !1.5% (Table 3).
Concomitant medications could also be used to
manage AEs during the DECISION study, either alongside
or independently of the study drug dose modifications.
The patient records for new concomitant medications
introduced over the course of the study showed that, for
example, dermatologic preparations were used more
frequently in sorafenib patients than in placebo patients.
These preparations included corticosteroids (used in 37%
vs 19% of sorafenib vs placebo patients respectively) and
emollients (34% vs 8%). Reasons for administering
concomitant medications were not captured, but it is
likely that these were employed to manage dermatologic
AEs. The same pattern was evident in use of antidiarrheal
medications (61% vs 17%) and antihypertensive medi-
cations such as agents acting on the renin–angiotensin
system (22% vs 5%) or calcium channel blockers (15%
vs 4%). These data, combined with findings from an
analysis of per patient data for treatment modifications
and AE reporting (Supplementary Figure 2, see section on
supplementary data given at the end of this article),
suggest that dose modifications in combination withhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0252
q 2015 The authors
Printed in Great Britainother supportive measures appeared to be effective at
reducing AE severity.Safety findings by treatment cycle
Dose modifications or discontinuations due to AEs
by treatment cycle When analyzed by treatment
cycle, the proportion of patients with a new or continuing
dose interruption in the sorafenib group was highest in
cycles 1 and 2 (37 and 28% of patients respectively) and
decreased thereafter (8–12% of patients in cycles 5–9;
Fig. 1A). The percentage of patients with a new sorafenib
dose reduction followed a similar pattern: in cycles 1 and
2, about 30% of these patients had a new dose reduction in
cycles 1 and 2; this subsequently declined over cycles 3–5
and was 4–8% of patients during cycles 5–9 (Fig. 1A). The
proportion of patients with a new dose reduction, or
continuing on a reduced dose implemented in a previous
treatment cycle was 30% in cycle 1, increasing in
subsequent cycles. It plateaued at w49–56% by cycle 3
(Fig. 1A). Discontinuations due to AEs were highest in
cycle 1 at 4%, and then occurred at a rate of w1–2% in
most subsequent cycles (Fig. 1A). The proportion of
patients who were receiving either the standard dose
(800 mg daily) or the next lower dose (600 mg daily) on
the final day in each cycle was relatively stable (w70%)
across cycles 1–9 (Fig. 1B).
Dose modifications were also reported in the placebo
group (Table 1). The rate of dose interruption was
generally consistent over cycles 1–9, with a range of
4–12%. The rate of new dose reductions in this group was
11% in cycle 1, then around 1–3% in cycles 2–9.Published by Bioscientifica Ltd.
Table 2 Overall incidence of treatment-emergent adverse events occurring in R10% of patients receiving sorafeniba
(safety population)
Adverse event
Sorafenib (nZ207), n (%) Placebo (nZ209), n (%)
Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4
Hand–foot skin reaction 158 (76.3) 42 (20.3) – 20 (9.6) 0 –
Diarrhea 142 (68.6) 11 (5.3) 1 (0.5) 32 (15.3) 2 (1.0) 0
Alopecia 139 (67.1) – – 16 (7.7) – –
Rash/desquamation 104 (50.2) 10 (4.8) 0 24 (11.5) 0 0
Fatigue 103 (49.8) 11 (5.3) 1 (0.5) 53 (25.4) 3 (1.4) 0
Weight loss 97 (46.9) 12 (5.8) – 29 (13.9) 2 (1.0) –
Hypertension 84 (40.6) 20 (9.7) 0 26 (12.4) 5 (2.4) 0
Serum TSH increase (MedDRA)b 69 (33.3) – – 28 (13.4) – –
Anorexia 66 (31.9) 5 (2.4) 0 10 (4.8) 0 0
Oral mucositis (functional/symptomatic) 48 (23.2) 1 (0.5) 1 (0.5) 7 (3.3) 0 0
Pruritus 44 (21.3) 2 (1.0) – 22 (10.5) 0 –
Nausea 43 (20.8) 0 – 24 (11.5) 0 –
Hypocalcemia 39 (18.8) 12 (5.8) 7 (3.4) 10 (4.8) 1 (0.5) 2 (1.0)
Headache 37 (17.9) 0 – 15 (7.2) 0 –
Cough 32 (15.5) 0 – 32 (15.3) 0 –
Constipation 31 (15.0) 0 0 17 (8.1) 1 (0.5) 0
Shortness of breath 30 (14.5) 10 (4.8) 0 28 (13.4) 4 (1.9) 2 (1.0)
Dry skin 30 (14.5) 1 (0.5) – 12 (5.7) 0 –
Abdominal pain 29 (14.0) 3 (1.4) 0 8 (3.8) 1 (0.5) 0
Limb pain 28 (13.5) 1 (0.5) 0 18 (8.6) 1 (0.5) 0
ALT 26 (12.6) 5 (2.4) 1 (0.5) 9 (4.3) 0 0
Voice changes 25 (12.1) 1 (0.5) 0 6 (2.9) 0 0
Fever 23 (11.1) 2 (1.0) 1 (0.5) 10 (4.8) 0 0
Vomiting 23 (11.1) 1 (0.5) 0 12 (5.7) 0 0
AST 23 (11.1) 2 (1.0) 0 5 (2.4) 0 0
Back pain 22 (10.6) 2 (1.0) 0 22 (10.5) 2 (1.0) 1 (0.5)
Pain in throat/pharynx/larynx 21 (10.1) 0 0 8 (3.8) 0 0
ALT, alanine transaminase; AST, aspartate transaminase; MedDRA, Medical Dictionary for Regulatory Activities; TSH, thyroid stimulating hormone.
aNonspecific AEs not included in this table: dermatology – other, metabolic/laboratory – other, and pain – other.
bStudy-specific AE including TSH concentrations O0.5 mIU/l. Maximum possible severity was grade 1.
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research F Worden et al. Sorafenib safety in
RAI-refractory DTC
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was 3.8%; 0–1% over cycles 1–5, then 0% in cycles 6–9.
By-cycle incidence and prevalence of common
AEs The by-cycle incidence of AEs in the sorafenib
group was generally highest in cycle 1 or 2, decreasing
subsequently. The prevalence of AEs in patients treatedTable 3 Study drug interruptions, reductions, and permanent disco
of treatment (safety population)
Adverse event
Sorafenib group (nZ207), n (%)
Interruption Reduction Disco
Hand–foot skin reaction 55 (26.6) 70 (33.8) 11
Rash/desquamation 18 (8.7) 16 (7.7) 3
Hypertension 16 (7.7) 12 (5.8) 1
Diarrhea 7 (3.4) 28 (13.5) 2
Fatigue 15 (7.2) 7 (3.4) 3
Weight loss 5 (2.4) 13 (6.3) 1
Hypocalcemia 4 (1.9) 6 (2.9) 1
http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0252
q 2015 The authors
Printed in Great Britainwith sorafenib tended to increase over the first two to six
cycles before stabilizing or declining. In the placebo arm,
no general patterns were evident in incidence or preva-
lence of any of the selected AEs over the first nine cycles
(Figs 2 and 3).
In the sorafenib group, the by-cycle incidence of HFSR
and rash/desquamation was highest in cycle 1, affectingntinuations due to specific adverse events over the entire course
Placebo group (nZ209), n (%)
ntinuation Interruption Reduction Discontinuation
(5.3) 0 2 (1.0) 0
(1.4) 0 0 0
(0.5) 3 (1.4) 1 (0.5) 0
(1.0) 2 (1.0) 1 (0.5) 0
(1.4) 3 (1.4) 3 (1.4) 0
(0.5) 2 (1.0) 1 (0.5) 2 (1.0)
(0.5) 0 0 0
Published by Bioscientifica Ltd.
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Figure 1
Patients with dose modifications and treatment discontinuations due to
AEs in each 28-day cycle of sorafenib treatment (intention-to-treat
population). Percentages were calculated using the patients at risk in each
cycle as the denominator. (A) Patients on interrupted or reduced dosesa,b,
or with new dose reductions or permanent discontinuations in each cycle.
(B) Patients at each dose level at the end of each cycle. aPatients on
interrupted dose were defined as those who during the treatment cycle
had a new interruption or an interruption continuing from the previous
cycle. bPatients on reduced dose were defined as those receiving at least
one daily dose of !800 mg during the treatment cycle. cPatients on 0 mg
dose at the end of the cycle includes patients who discontinued study drug
during the cycle in addition to patients on a dose interruption.
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The incidence of these AEs decreased exponentially, by
approximately half in each subsequent cycle, until cycle 4,
after which incidence stabilized. The prevalence of these
AEs was generally consistent throughout the first nine
cycles, with rates ofw40–60% for HFSR and of 20–30% for
rash. Over time, there was a shift in the severity of HFSR
and rash towards lower grades. The proportion of grade 2
and 3 HFSR was highest in cycle 1 and decreased over the
first five cycles with a concurrent increase in grade 1. The
proportion of grade 2 and 3 rash/desquamation followed
a similar pattern, but decreased more quickly, reaching a
plateau after cycle 3 (Fig. 2A, B, C and D).http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0252
q 2015 The authors
Printed in Great BritainIn patients receiving sorafenib, the incidence of
hypertension was highest in cycles 1 and 2. Hypertension
prevalence remained stable over cycles 1–9 at 22–25%.
The severity of hypertension in these patients was
generally consistent over time; for example, the
prevalence of grade 3 hypertension was within 2–5%
throughout cycles 1–9 (Fig. 2E and F).
In the sorafenib group, the by-cycle incidence of
diarrhea was highest in cycle 1 at 29%; new onset or
worsening of existing diarrhea was reported in 10–15%
of patients in each of cycles 2–6. Diarrhea was primarily
grade 1 throughout the first nine cycles. Its prevalence
increased steadily over the first six cycles, peaking in
cycle 6. This increase in overall prevalence was driven by
an increase in grade 1 diarrhea; the proportion of patients
with grade 2 or 3 diarrhea was generally consistent, at
6–10% in most cycles (Fig. 2G and H).
In the sorafenib group, fatigue showed the highest
incidence in cycle 1 (27%); the incidence by cycle was 7%
or lower in cycles 2–9. Fatigue prevalence was generally
stable over cycles 1–9, fluctuating within 26–33%.
Throughout the first nine cycles most fatigue was grade
1 or 2 and there was no clear shift in its severity over time
(Fig. 3A and B).
Rates of new or worsening weight loss in the sorafenib
group were highest during cycles 1–4. Prevalence
increased during cycles 1–7, after which it stabilized
(Fig. 2K and L). Weight loss was primarily grade 1 or 2.
Of the AEs analyzed here, only weight loss tended to
increase in severity over time, with a greater proportion of
patients with grade 2 toxicity in cycle 9 compared with
cycles 1 and 2 (Fig. 3C and D).
Increased serum TSH was a study-specific AE for which
grade 1 was the maximum defined severity (the few
reports of grade 2 increased TSH were due to errors in
grading). This AE was observed throughout the study in
the sorafenib group. Its incidence by cycle was low in cycle
1 (!1%), highest in cycle 2 (11%), and tended to decline
thereafter. The prevalence of increased TSH was also low in
cycle 1 (!1%); prevalence then rose from 12% in cycle 2 to
a peak of 19% in cycle 5, after which it steadily declined
to 13% by cycle 9 (Fig. 3E and F).
In the sorafenib group, hypocalcemia incidence was
highest in cycle 2 (7%). The prevalence of hypocalcemia
was low in cycle 1 (1%), and then generally stable at
8–11% over cycles 2–9. Most hypocalcemia was grade 1 or
2, although grade 3 and 4 events appeared early and were
observed throughout the first seven cycles (grade 4) and
nine cycles (grade 3) (Fig. 3G and H).Published by Bioscientifica Ltd.
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Figure 2
Incidence (onset or worsening) and prevalence (onset or persistence) per 28-day cycle, respectively, for hand–foot skin reaction (HFSR) (A and B),
rash/desquamation (C and D), hypertension (E and F), and diarrhea (G and H) during the double-blind treatment period (safety population).
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Detailed analysis of the AE occurrence patterns in patients
with RAI-refractory DTC in DECISION demonstrated that
most AEs with sorafenib were grade 1 or 2, started early
during the treatment course, and were typically manage-
able over time. The overall rate of discontinuation of
sorafenib due to AEs in DECISION was !20%, indicating
that in the majority of patients with RAI-refractory DTCA
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Figure 3
Incidence (onset or worsening) and prevalence (onset or persistence) per
28-day cycle, respectively, for fatigue (A and B), weight loss (C and D),
elevated TSH (E and F), and hypocalcemia (G and H) during the double-
http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0252
q 2015 The authors
Printed in Great Britainthe drug was well tolerated, with most discontinuations
due to AEs (4%) occurring in cycle 1. Similarly, the
proportion of grade 2 and 3 AEs tended to be fairly stable
or decline over time, with the exception of weight loss
where grade 2 increased in later cycles. The persistence of
AEs over the course of treatment argues for the continued
surveillance and management of patients receiving
sorafenib in this setting.C
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blind treatment period (safety population). Increased serum TSH was a
study-specific adverse event for which grade 1 was the maximum defined
severity. Reports of grade 2 increased TSH were due to errors in grading.
Published by Bioscientifica Ltd.
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22 :6 884AEs associated with sorafenib treatment were mana-
ged with a combination of dose modifications (treatment
interruptions and dose reductions) and concomitant use
of other medications such as antidiarrheals, antihyperten-
sives, or skin lotions. Although the effectiveness of these
AE management methods was not quantified, the low rate
of sorafenib discontinuation due to AEs beyond cycle 1
suggests that they were effective. Furthermore, the AE
management profiles for individual patients over time
again speak to the effectiveness of active management of
AEs for patients on the DECISION trial (Supplementary
Figure 2 given at the end of this article).
Some AEs, such as HFSR, alopecia, diarrhea, hyperten-
sion, squamous cell carcinoma of the skin, and hypocalce-
mia, were reported more frequently during the DECISION
trial than inthepivotalPhase3 trials of sorafenib in renal cell
carcinoma (RCC) and hepatocellular carcinoma (HCC)
(Llovet et al. 2008, Escudier et al. 2009, Brose et al. 2014a).
The overall proportions of sorafenib dose interruptions
(66%) and reductions (64%) in DECISION were also higher
than in the Phase 3 sorafenib HCC trials (the SHARP study:
44 and 26% respectively; Asia-Pacific study: not reported
and 31%) and RCC trial (TARGET study: 21 and 13%
respectively) (Escudier et al. 2007, Llovet et al. 2008, Cheng
et al. 2009, Brose et al. 2014a). Several factors could have
contributed to these differences. First, the median duration
of sorafenib therapy in DECISION (10.6 months) was
approximately twice as long as that in TARGET and SHARP
(both 5.3 months) allowing more time for events to occur
and for the dose to be modified in response (Escudier et al.
2007, Llovet et al. 2008). Also, compared with TARGET and
SHARP, the dose reduction scheme in DECISION allowed for
a more gradual reduction in sorafenib daily dose, from
800 mg, to 600 mg, to 400 mg, to 200 mg. Thus, patients in
DECISION received 600 mg/day on the first dose reduction
whereas in TARGET, SHARP, and the Asia-Pacific trial doses
were first reduced from 800 mg/day to 400 mg/day, and
then to 400 mg every other day (TARGET and SHARP) or
200 mg/day (Asia-Pacific study) (Escudier et al. 2007, Llovet
et al. 2008, Cheng et al. 2009).
It has been reported that AEs in patients treated
with sorafenib could be related to drug exposure
(Boudou-Rouquette et al. 2012, Pecuchet et al. 2012).
Sorafenib exposure in DECISION patients was higher than
that in patients with RCC or HCC (Bastholt et al. 2014),
and has been reported to decrease over time in patients
receiving unchanging dose (Arrondeau et al. 2012).
However, whereas higher sorafenib concentrations have
been correlated with increased rates of hypertension and
gradeR2 HFSR in other tumor types (Pecuchet et al. 2012),http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0252
q 2015 The authors
Printed in Great Britainand a trend towards a higher frequency of grade 2 AEs was
reported in patients with RAI-refractory DTC in patients
from DECISION receiving sorafenib, no significant corre-
lation was found between sorafenib exposure and AEs
(or PFS) (Bastholt et al. 2014). It is possible that AEs may
have been ameliorated over time due to declining drug
concentrations (Brose et al. 2015), although longitudinal
sorafenib exposure measurements were not made, and the
by-cycle incidence data reported here indicate that new or
worsening AEs occurred throughout cycles 1–9. The
reason behind the higher AE rates in DECISION thus
remains unclear (Brose et al. 2015).
Squamous cell carcinomas of the skin were more
common in sorafenib patients treated in DECISION than
in patients in the RCC and HCC pivotal studies (Llovet
et al. 2008, Escudier et al. 2009, Brose et al. 2014a), and so
skin cancer screening may be particularly important in
this patient group (Cabanillas et al. 2010, Brose et al.
2014a). Cutaneous squamous cell carcinomas have pre-
viously been associated with targeted therapies that
inhibit BRAF (Cabanillas et al. 2010). These additional
primary cancers can be benign or malignant and generally
respond well to timely intervention (Alam & Ratner 2001,
Cabanillas et al. 2010, Belum et al. 2015).
The overall incidence of HFSR reported in the
DECISION trial was higher than in the RCC and HCC
trials (Brose et al. 2014a). Although the study-specific HFSR
grading definitions used in the DECISION study were
more inclusive than the CTCAE v3.0 definitions used in
other studies (e.g. including dysesthesia and paresthesia
in grade 1 HFSR) and may have contributed to the higher
numbers, the 20% incidence of grade 3 HFSR exceeded
previous reports, which ranged from 6 to 11% (Escudier
et al. 2007, Llovet et al. 2008, Cheng et al. 2009). Dose
modifications and treatment discontinuations in
DECISION also occurred most often due to HFSR
(Table 3). Dose interruptions due to HFSR (26.6%) may
have been higher than those due to other AEs in part
because the study protocol mandated treatment interrup-
tion for skin toxicities as low as grade 2 (if the AE was not
resolved in 7 days or on second occurrence) whereas
treatment interruption for other AEs was not mandated
until grade 3 (with the exception of grade 2 hypertension)
(Supplementary Tables 1, 2, 3 and 4 given at the end of this
article). Because HFSR was the most commonly cited AE
leading to treatment discontinuation (5%), and because it
occurs early in treatment, prompt and effective manage-
ment of HFSR would seem to be critical in maintaining
patients on treatment. Most advice on the management of
HFSR is empiric (Edmonds et al. 2012). However, there isPublished by Bioscientifica Ltd.
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treatment with sorafenib that prophylactic use of a 10%
urea-based cream can delay HFSR as well as reduce its
incidence and severity (Ren et al. 2015). Data also suggest
that in cancer patients treated with sorafenib or sunitinib,
topical treatment of HFSR using a 40% urea cream in
combination with a 0.1% tazarotene cream or a 5%
fluorouracil cream twice daily is effective in reducing
HFSR severity (Lacouture et al. 2008). Additionally, dose
modifications in combination with symptomatic treat-
ment have rapidly resolved symptoms of grade 3 HFSR
in patients receiving sorafenib to treat RCC (Autier et al.
2008). HFSR prevention and management has been
reviewed in detail elsewhere (Edmonds et al. 2012, Brose
et al. 2014b, Walko & Grande 2014).
Only one patient discontinued treatment due to
hypertension and no cases of serious or grade 4 hyperten-
sion, such as hypertensive crisis, were reported. Diarrhea
and weight loss tended to increase in prevalence through-
out cycles 1–9. An increase in grade 1 events accounted for
the rise in diarrhea. A gradual increase in the prevalence of
diarrhea has also been reported in RCC patients treated
with sorafenib (Procopio et al. 2013). The severity of weight
loss is defined in terms of a decrease in weight from baseline
in CTCAE v3.0 (National Cancer Institute 2006), with grade
1 being a 5–10% reduction and no intervention required,
and grade 2 being a 10–20% reduction with nutritional
supplementation indicated. The higher proportion of grade
2 events seen in this study in later cycles may reflect the
cumulative effects of continuous, gradual weight loss in
some patients rather than a sign of accelerated weight loss.
TSH suppression is an important treatment interven-
tion in metastatic DTC (Cooper et al. 2009, Pacini et al.
2012); hence, elevated TSH was recorded as a study-
specific AE in the DECISION trial. TSH elevations with
sorafenib were typically transient. It was anticipated that
elevated TSH would occur more frequently with sorafenib
than with placebo because of the known interaction
between sorafenib and thyroid metabolism in athyreotic
patients (Gupta-Abramson et al. 2008, Abdulrahman et al.
2010, Verloop et al. 2013). Indeed, elevated TSH requiring
an increase in thyroid hormone replacement is considered
a class effect of tyrosine kinase inhibitors (Cabanillas et al.
2011). Increased serum TSH was reported in one-third of
sorafenib patients (Brose et al. 2014a); incidence was
highest in cycle 2, and !5% thereafter. Prevalence
increased gradually up to cycle 5. These results support
the monthly monitoring of TSH levels and the use of
thyroxine replacement medications, as appropriate (Bayer
HealthCare Pharmaceuticals, Inc. 2013).http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0252
q 2015 The authors
Printed in Great BritainGrade 3 or 4 hypocalcemia was reported with a
prevalence of 1–3% in the sorafenib group throughout
the first nine treatment cycles in DECISION. There was
one report of serious hypocalcemia and one patient
discontinued due to hypocalcemia. The small number of
transient grade 3 and 4 hypocalcemia events in the
placebo group underlines the fact that hypocalcemia is
a known postoperative complication of thyroidectomy
(Gonc¸alves & Kowalski 2005, Asari et al. 2008) and is
therefore specifically related to the patient population
studied in DECISION.
These results have implications for the optimal
management of RAI-refractory DTC patients receiving
sorafenib. In general, AEs and the resultant dose modifi-
cation, including discontinuations, tended to occur early.
Once stabilized, discontinuations due to AEs were
infrequent. Therefore, these results suggest that increased
attention to AEs early in the course of treatment coupled
with timely dose modifications may help to maximize
the number of patients who can stay on therapy and
potentially benefit from treatment.
Supplementary data
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